The views expressed on this website represent the opinions of Ancora Holdings Group, LLC (“Ancora”) and the other participants in its solicitation (collectively, the “Participants”), which beneficially own shares of Elanco Animal Health Incorporated (the “Company”), and are based on publicly available information with respect to the Company. The Participants recognize that there may be confidential information in the possession of the Company that could lead it or others to disagree with the Participants’ conclusions. The Participants reserve the right to change any of the opinions expressed herein at any time as they deem appropriate and disclaim any obligation to notify the market or any other party of any such changes. The Participants disclaim any obligation to update the information or opinions contained on this website.
Certain financial projections and statements made herein have been derived or obtained from filings made with the Securities and Exchange Commission (“SEC”) or other regulatory authorities and from other third party reports. Neither the Participants nor any of their affiliates shall be responsible or have any liability for any misinformation contained in any third party SEC or other regulatory filing or third party report. There is no assurance or guarantee with respect to the prices at which any securities of the Company will trade, and such securities may not trade at prices that may be implied herein. The estimates, projections and potential impact of the opportunities identified by the Participants herein are based on assumptions that the Participants believe to be reasonable as of the date of the materials on this website, but there can be no assurance or guarantee that actual results or performance of the Company will not differ, and such differences may be material.
The materials on this website are provided merely as information and are not intended to be, nor should they be construed as, an offer to sell or a solicitation of an offer to buy any security. These materials do not recommend the purchase or sale of any security. The Participants currently beneficially own shares of the Company. It is possible that there will be developments in the future that cause the Participants from time to time to sell all or a portion of their holdings of the Company in open market transactions or otherwise (including via short sales), buy additional shares (in open market or privately negotiated transactions or otherwise), or trade in options, puts, calls or other derivative instruments relating to such shares.
Although the Participants believe the statements made in this website are substantially accurate in all material respects and does not omit to state material facts necessary to make those statements not misleading, the Participants make no representation or warranty, express or implied, as to the accuracy or completeness of those statements or any other written or oral communication it makes with respect to the Company and any other companies mentioned, and the Participants expressly disclaim any liability relating to those statements or communications (or any inaccuracies or omissions therein). Thus, stockholders and others should conduct their own independent investigation and analysis of those statements and communications and of the Company and any other companies to which those statements or communications may be relevant.
This website may contain links to articles and/or videos (collectively, “Media”). The views and opinions expressed in such Media are those of the author(s)/speaker(s) referenced or quoted in such Media and, unless specifically noted otherwise, do not necessarily represent the opinion of the Participants.
This website may not be deemed to constitute solicitation material and is intended solely to inform stockholders so that they may make an informed decision regarding the proxy solicitation, as explained in greater detail below.
The materials on this website contain forward-looking statements. All statements contained herein that are not clearly historical in nature or that necessarily depend on future events are forward-looking, and the words “anticipate,” “believe,” “expect,” “potential,” “opportunity,” “estimate,” “plan,” and similar expressions are generally intended to identify forward-looking statements. The projected results and statements contained herein that are not historical facts are based on current expectations, speak only as of the date of these materials and involve risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such projected results and statements. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Participants. Although the Participants believe that the assumptions underlying the projected results or forward-looking statements are reasonable as of the date of these materials, any of the assumptions could be inaccurate and therefore, there can be no assurance that the projected results or forward-looking statements included herein will prove to be accurate. In light of the significant uncertainties inherent in the projected results and forward-looking statements included herein, the inclusion of such information should not be regarded as a representation as to future results or that the objectives and strategic initiatives expressed or implied by such projected results and forward-looking statements will be achieved. The Participants will not undertake and specifically declines any obligation to disclose the results of any revisions that may be made to any projected results or forward-looking statements herein to reflect events or circumstances after the date of such projected results or statements or to reflect the occurrence of anticipated or unanticipated events.
This website may employ cookies. The publicly accessible areas of this website do not automatically gather any personal information, and such information will not be collected unless information such as your name, phone number or e-mail address is provided voluntarily. However, we reserve the right to gather non-personal information and perform statistical analysis of user behavior and patterns of this website.
I have read and agree to the terms of this website.
Join us in urging regulators and lawmakers to protect the rights of closed-end fund investors.
Submit a Comment to the SEC on the NYSE’s Section 302 Rule Amendment Proposal by July 30th:
To express your opposition to the proposal, submit your comments directly to the SEC by completing this form by the July 30th deadline.
Submit a comment to share your experience investing in closed-end funds and to tell the SEC why you believe being able to hold trustees accountable through annual elections is a crucial right that must be protected.
In your comment, we encourage you to (1) highlight why trustees shouldn't be appointed for life, (2) emphasize why shareholders – as owners – deserve the right to determine who represents them, and (3) express your concerns that when annual meetings are not held, closed-end funds trade at larger discounts and investors can face billions of dollars in losses.
Submit a Comment to the SEC on The CBOE's Proposal to Adopt Rule 14.10(e)(1)(E)(iv) by August 5th:
To express your opposition, submit your comments directly to the SEC by completing this form by the August 5th deadline.
Submit a comment to share your experience investing in closed-end funds and to tell the SEC why you believe being able to hold trustees accountable through annual elections is a crucial right that must be protected.
Call or Email Your Members of Congress, Encouraging Them to Urge the SEC to Oppose the NYSE and CBOE Proposals:
Click here to identify your senator and find their relevant contact details.
Click here to identify your congressional representative to find their relevant contact details.
Call or Email Your Senators to Urge Them to Oppose H.R. 2799:
Click here to identify your senator and find their relevant contact details.
You can reach your senator via phone, email, mail or via posting on social media platforms such as Twitter and Facebook.
Sign Saba’s Petition Urging the SEC to Reject the NYSE’s Proposal:Click here to sign our petition to urge the SEC to reject the NYSE’s proposal and protect the rights of closed-end fund shareholders.
Raise Your Voice via Social Media: Join the conversation on social media by sharing your opposition to the NYSE proposal, the CBOE proposal and H.R. 2799 along with the hashtag #ProtectCEFInvestors.